Dent S, Cortes J, Im YH, Dieras V, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol 2020 Nov 10. pii: S0923-7534(20)43124.
PMID: 33186740